Titan Pharmaceuticals, Inc.

Navigate Titan Pharmaceuticals, Inc.

  • Home
  • About
    • Overview
    • Who We Are
    • IP Portfolio
    • Management Team
    • Board of Directors
    • Careers
  • Technology
  • Pipeline
    • Kappa Opioid Receptor Agonist
    • Nalmefene Implant
  • News
    • Overview
    • Press Releases
    • Events
    • Presentations
    • In the News
    • Publications
    • Posters
    • Media Resources
  • Investors
    • Investor Relations
    • Overview
    • News / Events
    • Press Releases
    • IR Calendar
    • Email Alerts
    • Company Info
    • Company Information
    • Profile
    • Presentations
    • Management Team
    • Contacts
    • FAQ
    • Titan FCOI Policy
    • Stock Data
    • Quote
    • Charts
    • Historical Data
    • SEC Filings
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
    • Governance
    • Board of Directors
    • Board Committees
    • Governance Documents
  • Contact
  • Search

Press Releases

  • Home
  • News
  • Press Releases
News

Navigate News

  • Overview
  • Press Releases
  • Events
  • Presentations
  • In the News
  • Publications
  • Posters
  • Media Resources

Press Releases

  • All News
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013
  • 2012
  • 2011
  • 2010
  • 2009

Titan Pharmaceuticals Provides Update on Confirmatory Phase 3 Study of Probuphine

June 17, 2011

Titan Pharmaceuticals Announces First Quarter 2011 Financial Results

May 16, 2011

Titan Pharmaceuticals Reports Fourth Quarter and Full Year 2010 Financial Results

March 24, 2011

Titan Pharmaceuticals Enters Into a $20 Million Credit Facility With Deerfield Management

March 16, 2011

Titan Reports Fourth Quarter 2010 FanaptĀ® Royalty

February 4, 2011

  • « Previous
  • 1
  • 2
© 2022 Titan Pharmaceuticals, Inc. All Rights Reserved.
Privacy Policy Titan FCOI Policy Disclaimer Sitemap